Moly Mining on the Continental Divide

Source: Steel Guru (3/14/11)

"The Continental Divide region could meet 100% of global moly demand."

A boundary along the Rocky Mountains that separates river systems into the two great oceans is also home to the world's most important molybdenum-producing regions. Early settlers came for the vast deposits of gold and silver but found many other deposits besides precious metals. The Climax Molybdenum mine was once the world's main molybdenum producer, responsible for three-quarters of global supply.

To examine the region's molybdenum potential, one must look on the outskirts of the Rockies, into the surrounding areas that also produce massive copper molybdenum deposits like Utah's Bingham Canyon Mine and some sizeable deposits in Nevada. The Continental Divide region arguably hosts the world's most important moly producing deposits.

The Henderson Mine has produced 770 million pounds (Mlb.) of molybdenum since 1976. The Climax mine is capable of putting 30 Mlb. molybdenum into the market and because mining was conducted at the site for years, the start up should be relatively easy. There are reports that the mine is coming back online in the near future. . .the main factor that could keep full production from starting is the reported surplus of moly currently on the market that could keep prices at bay in 2011.

Bingham Canyon is the most important copper moly mine in the U.S., if not the world. Located just outside Salt Lake City, Utah, it has produced more copper than any mine in the world over its lifetime. In 2009, the mine produced 24.9 Mlb. molybdenum.

The CUMO project in Idaho features one of the largest moly deposits in the world. The resource base has an I&I resource of 4.1 billion pounds molybdenum oxide and massive amounts of copper, silver and tungsten.

The Continental Divide is one of the world's most-prolific molybdenum regions and, at full production, could meet 100% of global moly demand.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.